Real-World Evidence of Safety and Efficacy of Carboplatin Plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study

Overview

Journal Can Respir J

Publisher Wiley

Specialty Pulmonary Medicine

Date 2019 Apr 25

PMID 31015884

Citations 6

Authors

Tomoyuki Araya

Toshiyuki Kita

Tsukasa Ueda

Nanao Terada

Tamami Sakai

Kenta Yamamura

Koji Kurokawa

Yuka Uchida

Takashi Sone

Hideharu Kimura

Kazuo Kasahara

Affiliations

Soon will be listed here.

Abstract

Background: Standard chemotherapy for advanced non-small-cell lung cancer (NSCLC) with preexisting interstitial lung disease (ILD) has not yet been established. Although a combination of carboplatin and paclitaxel is most frequently used for patients with advanced NSCLC and ILD, the safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) are yet to be elucidated.

Objectives: This study aimed to evaluate the safety and efficacy of carboplatin plus nab-paclitaxel for advanced NSCLC with ILD.

Methods: This retrospective study included nine patients with advanced NSCLC and ILD who received carboplatin plus nab-paclitaxel as first-line chemotherapy at the National Hospital Organization Kanazawa Medical Center between April 2013 and December 2017. The ILD-GAP index was used to evaluate mortality risk of baseline ILD.

Results: A usual interstitial pneumonia (UIP) pattern of ILD was observed in five (55.6%) patients on their baseline high-resolution computed tomography (HRCT) scans. The median ILD-GAP index was 4 (range, 1-5), and six (66.7%) patients had ILD-GAP index ≥4. We observed no ILD exacerbations or chemotherapy-related deaths. The overall response and disease control rates were 77.8% (95% CI, 40.0-97.2) and 88.9% (95% CI, 51.8-97.2), respectively. The median progression-free survival and overall survival were 5.8 months (95% CI, 2.1-7.7) and 8.0 months (95% CI, 2.6-16.8), respectively.

Conclusions: Carboplatin plus nab-paclitaxel showed favorable safety and efficacy in patients who had advanced NSCLC and ILD with a high risk of mortality. Prospective studies are required to further confirm these results.

Citing Articles

Case report: Idiopathic pulmonary fibrosis induced by nab-paclitaxel: A rare complication.

Shen J, Wen Z, Lin J, Su H Front Pharmacol. 2023; 14:1094844.

PMID: 36909189 PMC: 9995582. DOI: 10.3389/fphar.2023.1094844.

Anti-Angiogenic Drugs Inhibit Interstitial Lung Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer.

Wang Y, Gong X, Hu Y, Yi Q, Zhang Q, Miao L Front Oncol. 2022; 12:873709.

PMID: 35795057 PMC: 9251331. DOI: 10.3389/fonc.2022.873709.

A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114).

Sakashita H, Uchibori K, Jin Y, Tsutsui T, Honda T, Sakakibara R Thorac Cancer. 2022; 13(9):1267-1275.

PMID: 35322551 PMC: 9058300. DOI: 10.1111/1759-7714.14376.

Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen.

Hao X, Zhu Y, Mu Y, Wang S, Li J, Xing P J Cancer. 2020; 11(21):6421-6428.

PMID: 33033525 PMC: 7532494. DOI: 10.7150/jca.47072.

The Efficacy and Safety of First-Line Chemotherapy in Patients With Non-small Cell Lung Cancer and Interstitial Lung Disease: A Systematic Review and Meta-Analysis.

Wang Y, Miao L, Hu Y, Zhou Y Front Oncol. 2020; 10:1636.

PMID: 33014824 PMC: 7506119. DOI: 10.3389/fonc.2020.01636.

References

Kenmotsu H, Naito T, Mori K, Ko R, Ono A, Wakuda K . Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemother Pharmacol. 2015; 75(3):521-6. DOI: 10.1007/s00280-014-2670-y. View

Sekine A, Satoh H, Baba T, Ikeda S, Okuda R, Shinohara T . Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study. Cancer Chemother Pharmacol. 2016; 77(6):1245-52. DOI: 10.1007/s00280-016-3040-8. View

Satouchi M, Okamoto I, Sakai H, Yamamoto N, Ichinose Y, Ohmatsu H . Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2013; 81(1):97-101. DOI: 10.1016/j.lungcan.2013.02.020. View

Omori T, Tajiri M, Baba T, Ogura T, Iwasawa T, Okudela K . Pulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia. Ann Thorac Surg. 2015; 100(3):954-60. DOI: 10.1016/j.athoracsur.2015.03.094. View

Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S . Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2006; 18(2):317-23. DOI: 10.1093/annonc/mdl377. View

Doebele R, Conkling P, Traynor A, Otterson G, Zhao Y, Wind S . A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2012; 23(8):2094-2102. PMC: 4141207. DOI: 10.1093/annonc/mdr596. View

Forster M, Hackshaw A, De Pas T, Cobo M, Garrido P, Summers Y . A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3). Lung Cancer. 2018; 120:27-33. DOI: 10.1016/j.lungcan.2018.03.007. View

Raghu G, Remy-Jardin M, Myers J, Richeldi L, Ryerson C, Lederer D . Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198(5):e44-e68. DOI: 10.1164/rccm.201807-1255ST. View

Yasuda Y, Hattori Y, Tohnai R, Ito S, Kawa Y, Kono Y . The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease. Jpn J Clin Oncol. 2017; 48(1):89-93. DOI: 10.1093/jjco/hyx142. View

10.

Lynch D, Sverzellati N, Travis W, Brown K, Colby T, Galvin J . Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2017; 6(2):138-153. DOI: 10.1016/S2213-2600(17)30433-2. View

11.

Shukuya T, Ishiwata T, Hara M, Muraki K, Shibayama R, Koyama R . Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease. Anticancer Res. 2010; 30(10):4357-61. View

12.

Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K . Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2013; 147(5):1604-1611.e3. DOI: 10.1016/j.jtcvs.2013.09.050. View

13.

Azadeh N, Limper A, Carmona E, Ryu J . The Role of Infection in Interstitial Lung Diseases: A Review. Chest. 2017; 152(4):842-852. PMC: 7094545. DOI: 10.1016/j.chest.2017.03.033. View

14.

Goldstraw P, Crowley J, Chansky K, Giroux D, Groome P, Rami-Porta R . The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2(8):706-14. DOI: 10.1097/JTO.0b013e31812f3c1a. View

15.

Kim D, Park J, Park B, Lee J, Nicholson A, Colby T . Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006; 27(1):143-50. DOI: 10.1183/09031936.06.00114004. View

16.

Otsubo K, Kishimoto J, Kenmotsu H, Minegishi Y, Ichihara E, Shiraki A . Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. Clin Lung Cancer. 2017; 19(1):e5-e9. DOI: 10.1016/j.cllc.2017.06.003. View

17.

Shimizu R, Fujimoto D, Kato R, Otoshi T, Kawamura T, Tamai K . The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease. Cancer Chemother Pharmacol. 2014; 74(6):1159-66. DOI: 10.1007/s00280-014-2590-x. View

18.

Hanna N, Kaiser R, Sullivan R, Aren O, Ahn M, Tiangco B . Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. Lung Cancer. 2016; 102:65-73. DOI: 10.1016/j.lungcan.2016.10.011. View

19.

Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Y . The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol. 2011; 6(7):1242-6. DOI: 10.1097/JTO.0b013e318216ee6b. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View